Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
Article 2017 en
Authors
JE
John W. Eikelboom
SC
Stuart J. Connolly
JB
Jackie Bosch
Abstract
1 min read
Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424 .).
John W. Eikelboom, Jackie Bosch, Stuart J. Connolly, Olga Shestakovska, Gilles R. Dagenais, Robert G. Hart, Darryl P. Leong, Martin O’Donnell, Keith A.A. Fox, Deepak L. Bhatt, John A. Cairns, Christoph Tasto, Scott D. Berkowitz, Nancy Cook Bruns, Eva Muehlhofer, Rafael Díaz, Aldo Maggioni, Salim Yusuf
Thomas Vanassche, Peter Verhamme, Darryl P. Leong, Deepak L. Bhatt, Olga Shestakovska, Aldo Maggioni, Keith A.A. Fox, Eva Muehlhofer, Stuart J. Connolly, Salim Yusuf, John W. Eikelboom, Jackie Bosch
Mukul Sharma, Robert G. Hart, Stuart J. Connolly, Jackie Bosch, Olga Shestakovska, Kelvin Kuan Huei Ng, Luciana Catanese, Katalin Keltai, Victor Aboyans, Marco Alings, Jong‐Won Ha, George Varigos, Andrew Tonkin, Martin O’Donnell, Deepak L. Bhatt, Keith A.A. Fox, Aldo Maggioni, Scott D. Berkowitz, Nancy Cook Bruns, Salim Yusuf, John W. Eikelboom
Deepak L. Bhatt, John W. Eikelboom, Stuart J. Connolly, Philippe Gabríel Steg, Sonia S. Anand, Subodh Verma, Kelley R. Branch, Jeffrey L. Probstfield, Jackie Bosch, Olga Shestakovska, Michael Szarek, Aldo Maggioni, Petr Widimský, Álvaro Avezum, Rafael Díaz, Basil S. Lewis, Scott D. Berkowitz, Keith A.A. Fox, Lars Rydén, Salim Yusuf, Victor Aboyans, Marco Alings, Patrick Commerford,
Discussion(0)
No comments yet. Be the first to comment.